Annovis BioÂ Inc (ANVS)

Name: Annovis BioÂ Inc (ANVS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Annovis BioÂ Inc (ANVS)

Stock Card

$1.70

$0.01 (0.59%)

As on 02-Sep-2026 16:22EDT

Market cap

$76 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

25.2

Div. Yield

0 %

Annovis BioÂ Inc (ANVS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.69 High: 1.76

52 Week Range

Low: 1.54 High: 5.50

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-3.6
Debt to Equity

0
Book Value

$--
EPS

$-1.8
Face value

--
Shares outstanding

42,606,152

7 Years Aggregate

CFO

$-71.96 Mln

EBITDA

$-92.69 Mln

Net Profit

$-101.74 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Annovis BioÂ Inc (ANVS)	-50.9	-2.9	-6.6	-26.4	-48.4	-46.0	--
BSE Sensex^*	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Sep-2026 | *As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
Annovis BioÂ Inc (ANVS)	-31.2	-72.8	39.2	-23.6	133.2
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Annovis BioÂ Inc (ANVS)	1.7	76.3	0.0	-49.5	--	--	--	25.2
Arrowhead Pharmaceuticals (ARWR)	85.4	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	267.3	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	71.9	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	58.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	109.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	369.2	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	546.9	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	593.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	357.5	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Annovis BioÂ Inc (ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label... phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Read more

Founder, CEO, President & Executive Director

Dr. Maria L. Maccecchini Ph.D.
Founder, CEO, President, Interim Principal Financial Officer & Executive Director

Dr. Maria L. Maccecchini Ph.D.
Headquarters

Malvern, PA
Website

https://www.annovisbio.com

FAQs for Annovis BioÂ Inc (ANVS)

What is the current share price of Annovis BioÂ Inc (ANVS) Today?

The share price of Annovis BioÂ Inc (ANVS) is $1.70 (NYSE) as of 02-Sep-2026 16:22 EDT. Annovis BioÂ Inc (ANVS) has given a return of -48.35% in the last 3 years.

What is the current PB & PE ratio of Annovis BioÂ Inc (ANVS)?

Since, TTM earnings of Annovis BioÂ Inc (ANVS) is negative, P/E ratio is not available.
The P/B ratio of Annovis BioÂ Inc (ANVS) is 25.18 times as on 21-Aug-2026, a 386 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-2.98	5.09
2024	-2.82	7.46
2023	-3.17	-22.98
2022	-4.36	3.87
2021	-9.83	3.20

What is the 52 Week High and Low of Annovis BioÂ Inc (ANVS)?

The 52-week high and low of Annovis BioÂ Inc (ANVS) are Rs 5.50 and Rs 1.54 as of 03-Sep-2026.

What is the market cap of Annovis BioÂ Inc (ANVS)?

Annovis BioÂ Inc (ANVS) has a market capitalisation of $ 76 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Annovis BioÂ Inc (ANVS)?

Before investing in Annovis BioÂ Inc (ANVS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.